Key facts
- This page summarizes Jeff Fairman's Form 4 filing for Vaxcyte, Inc. (PCVX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 04 Jan 2023, 15:33.
Jeff Fairman - 30 Dec 2022 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)
- Reporting relationship
- VP, Research
- Issuer ticker
- PCVX
- Reported as of
- 30 Dec 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Jan 2023, 15:33:18 UTC
- Prior SEC filing
- 28 Oct 2022
- Source filing
- View source filing
- Reporting owner signature
- Jeff Fairman, by /s/ Ron A. Metzger, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Jeff Fairman filed Form 4 for Vaxcyte, Inc. (PCVX) on 04 Jan 2023.
Change
- Previous filing in this sequence was filed on 28 Oct 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PCVX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 17,827
- Date
- 30 Dec 2022
- Ownership
- Direct
- Footnotes
- F1
PCVX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 286,227
- Date
- 30 Dec 2022
- Ownership
- By Fairman Family Trust
PCVX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 50,000
- Date
- 30 Dec 2022
- Ownership
- By AF 2020 Irrevocable Trust
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PCVX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +15,000
- Change %
- Price
- $0.000000
- Shares after
- 15,000
- Date
- 30 Dec 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,000
- Exercise price
- $47.95
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Jeff Fairman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
Includes 684 shares acquired under the Issuer's Employee Stock Purchase Plan on November 17, 2022.
Footnote F2
1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.